What Servier Ireland does

Servier Ireland is the Irish operating arm of the Servier Group, a France-headquartered, non-profit Foundation-governed global pharmaceutical company. The Irish presence comprises two private limited companies: Servier Laboratories (Ireland) Ltd., established in 1974 and based in Dublin, which promotes and distributes the Group's prescription medicines across the Irish market and runs medical-information and continuous-medical-education programs for Irish physicians and pharmacists; and Servier (Ireland) Industries Ltd. (Servier Arklow), established in 1989 on a 60-acre site in Arklow, Co. Wicklow, which is the largest Servier manufacturing facility outside France and the second-largest in the Group network. Servier Arklow employs approximately 500 staff across 10 departments and produces 160+ million boxes of oral solid-dose tablets annually for export to over 100 countries, with capabilities spanning wet granulation, direct compression, aqueous-based tablet coating, tablet printing, and serialisation/aggregation for track-and-trace compliance.

The portfolio marketed in Ireland spans three core therapeutic areas - cardiometabolism (Coversyl Arginine, Coversyl Arginine Plus, Acerycal, Coverdine, Natrilix SR, Diamicron MR, Lipercosyl, Lipocomb), oncology (Tibsovo/ivosidenib, Lonsurf, Oncaspar, Onivyde, Pixuvri) and neuroscience (Valdoxan, Procoralan, Vastarel) - distributed on prescription through Irish pharmacies. The Group is the third-largest pharmaceutical company globally in cardiology and hypertension, holds the world's first approved mutant IDH1 inhibitor (Tibsovo), and reinvests close to 20% of brand-name revenue into R&D, with over 50% of R&D allocated to oncology.

Revenue mechanics combine export-driven contract-style manufacturing for the parent Group from Arklow with a small Irish product-sales motion through Servier Laboratories (Ireland) Ltd. Pricing for prescription medicines is not publicly disclosed. The subsidiary is led by Pascal Baraffe (General Manager, Arklow), with senior functional heads across HR, EHS & CSR and Quality at the Arklow site; at the Group level, Nicolas Garnier was appointed Chief Patient Officer in December 2023. Servier Group reported €4.9 billion revenue for the 2021/2022 financial year, distributing in close to 140-150 countries with 22,000 employees worldwide; Servier Ireland-specific standalone revenue is not disclosed but is in the hundreds of millions of euros range based on headcount and box-volume proxies.

Name

Servier Ireland

Legal name

Servier Laboratories (Ireland) Ltd. and Servier (Ireland) Industries Ltd.

Website

https://servier.ie

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

101–250 employees

Short description

Servier Ireland is the Irish subsidiary of the Servier Group, operating a 500+ staff pharmaceutical manufacturing facility in Arklow producing 160+ million boxes of oral solid-dose tablets annually for export to 100+ countries, alongside a Dublin-based affiliate that markets prescription medicines across cardiometabolism, oncology and neuroscience therapeutic areas to Irish physicians, pharmacists and patients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing & Distribution

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Prescription pharmaceutical products
• Oncology medicines
• Cardiovascular drug therapy
• Oral solid dose manufacturing
• Pharmaceutical distribution Ireland

Headquarters

HQ city

Arklow

HQ country

Ireland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Servier generates revenue through the sale of prescription pharmaceutical products including cardiovascular medicines, diabetes treatments, neuroscience drugs, and oncology medicines. Products are distributed through pharmacies and healthcare providers in Ireland and exported to over 100 countries.
2. Generic Pharmaceuticals: Servier offers a range of quality generic drugs covering most pathologies through strong brands in France, Eastern Europe, Brazil, and Nigeria.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Servier Ireland manufactures prescription pharmaceutical products at its Arklow facility (the largest Servier production site outside France) and distributes Servier medicines on the Irish market. Through Servier (Ireland) Industries Ltd., the company produces oral solid-dose tablets for oncology, cardiometabolism, venous diseases, and neurology (160+ million boxes annually, exported to 100+ countries). Through Servier Laboratories (Ireland) Ltd., the company promotes and distributes Servier medicines in Ireland, providing medical information and continuous medical education to healthcare professionals.

Product overview

Servier Ireland operates as a pharmaceutical company offering a portfolio of prescription medicines across three core therapeutic areas: Cardiometabolism (antihypertensives including ACE inhibitors, calcium channel blockers, diuretics, and antidiabetics), Oncology (cancer treatments including targeted therapies and chemotherapeutic agents), and Neuroscience (antidepressants and other neurological medications). The company distributes both branded originator medicines and generic products, with major product lines including Coversyl, Diamicron MR, Valdoxan, Oncaspar, Onivyde, and Lonsurf. Servier Ireland also provides a digital patient support platform called MyHealthPartner.ie developed in partnership with the Global Heart Hub, offering cardiovascular disease education and lifestyle tools. The Arklow manufacturing site produces oral solid-dose tablets exported to over 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

• MyHealthPartner.ie: Cardiovascular patient website developed by Servier in collaboration with Global Heart Hub, providing information on chronic diseases including hypertension
• #BecauseIsayso
• It's Cardiac Rehab!
• Leukaemia CAST

Products and services

• Tibsovo (ivosidenib) A 250 mg film-coated tablet for the treatment of certain cancers, specifically a mutant IDH1 inhibitor approved in the U.S. and European Union.
• Acerycal (Perindopril Arginine, Amlodipine) A fixed-dose combination antihypertensive medication combining an ACE inhibitor with a calcium channel blocker for the treatment of hypertension.
• Coverdine (Amlodipine/Indapamide/Perindopril) A triple-combination antihypertensive tablet available in multiple dosages (5mg/1.25mg/5mg, 5mg/1.25mg/10mg, 10mg/2.5mg/5mg, 10mg/2.5mg/10mg) combining a calcium channel blocker, diuretic, and ACE inhibitor.
• Coversyl Arginine (Perindopril Arginine) An ACE inhibitor antihypertensive medication available in 5mg and 10mg dosages for the treatment of hypertension and cardiovascular conditions.
• Coversyl Arginine Plus (Perindopril Arginine, Indapamide) A combination antihypertensive medication pairing an ACE inhibitor with a diuretic, available in multiple strengths (2.5mg/0.625mg, 5mg/1.25mg, 10mg/2.5mg) for blood pressure control.
• Diamicron MR (Gliclazide) A modified-release sulfonylurea antidiabetic medication available in 30mg and 60mg dosages for the management of type 2 diabetes mellitus.
• Lonsurf (Trifluridine/Tipiracil) An oral antimetabolite combination medication used in the treatment of metastatic colorectal cancer.
• Natrilix SR (Indapamide) A sustained-release thiazide-like diuretic antihypertensive medication for the treatment of hypertension.
• Oncaspar (Pegaspargase) A pegylated asparaginase medication used as part of combination chemotherapy for the treatment of acute lymphoblastic leukaemia.
• Onivyde Pegylated Liposomal (Irinotecan) A pegylated liposomal formulation of irinotecan used in the treatment of metastatic pancreatic cancer.
• Procoralan (Ivabradine) A heart rate-reducing agent that works by inhibiting the If current in the sinoatrial node, used for the treatment of stable angina and chronic heart failure.
• Valdoxan (Agomelatine) A 25mg film-coated tablet antidepressant medication that acts as an MT1 and MT2 melatonin receptor agonist and 5-HT2C receptor antagonist for the treatment of major depressive disorder.
• Vastarel (Trimetazidine) A 20mg antianginal medication used to increase coronary flow reserve and reduce myocardial ischemia in patients with angina.
• Lipercosyl (Atorvastatin/Perindopril) A fixed-dose combination medication pairing a statin with an ACE inhibitor for cardiovascular risk reduction.
• Lipocomb (Ezetimibe/Rosuvastatin) A fixed-dose combination medication pairing a cholesterol absorption inhibitor with a statin for the treatment of hypercholesterolaemia.
• Pixuvri (Pixantrone) An anthracenedione antineoplastic agent used for the treatment of aggressive B-cell non-Hodgkin lymphoma.
• MyHealthPartner.ie A free cardiovascular patient website developed by Servier in collaboration with the Global Heart Hub, providing chronic disease information, personalised recipes, lifestyle guidance, and treatment support tools to Irish patients and healthcare professionals.
• Servier Medical Art A medical image bank provided by Servier that offers freely usable medical illustrations for illustrating medical releases and educational content.

Quantifiable outcome

• 22,000 employees worldwide committed to therapeutic progress
• +5 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Arklow Cancer SupportminorOthers · 27 October 2023Servier Arklow raised €5,130.50 for Arklow Cancer Support through the Never Give Up Challenge 2023, with 331 participants from Servier Arklow and Servier Dun Laoghaire.
• International Society of HypertensioncoreStrategic or Co-development Partner · 1 May 2023Servier supports May Measure Month screening initiative from the International Society of Hypertension to combat low diagnosis rates of hypertension worldwide.
• Children's Health Ireland (CHI) at CrumlincoreStrategic or Co-development Partner · 21 September 2022Partnership with Children's Health Ireland to support Leukaemia CAST podcast series for parents of children and young people with Acute Lymphoblastic Leukaemia (ALL).
• Global Heart HubcoreStrategic or Co-development Partner · 9 September 2022Collaboration with Global Heart Hub (patient organization) to develop MyHealthPartner.ie - an all-in-one cardiovascular patient website providing certified health information, personalized recipes, and lifestyle guidance.
• Irish Heart FoundationcoreStrategic or Co-development Partner · 1 July 2022Partnership with Irish Heart Foundation to develop 'It's Cardiac Rehab!' podcast series encouraging patients who have suffered cardiac events to sign up for cardiac rehabilitation.
• Irish Association of Cardiac Rehabilitation (IACR)coreStrategic or Co-development Partner · 1 July 2022Partnership to develop 'It's Cardiac Rehab!' podcast series for patients who have had cardiovascular events to help them understand cardiac rehabilitation programs.
• Business in the Community IrelandminorOthersServier Arklow partners with Business in the Community Ireland for wellness programs supporting employee wellbeing.
• VHI HealthcareminorOthersServier Arklow works with VHI Healthcare as wellness partners for employee health programs.

Scale indicators14 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Merck KGaA: Family/foundation-influenced, mid-size German pharmaceutical and life sciences group with diversified specialty pharma, oncology, and neurology exposure. Comparable to Servier in private ownership structure, therapeutic breadth, and European manufacturing base.
• Ipsen: European privately held specialty pharmaceutical group focused on oncology, neuroscience, and rare disease, with comparable mid-size scale and similar pivot toward higher-value specialty products from a legacy primary-care base.
• Menarini Group: Privately held Italian pharmaceutical company with significant cardiometabolic and specialty presence across Europe and emerging markets. Comparable to Servier in private ownership, strong European manufacturing footprint, and broad cardiometabolic portfolio.
• Daiichi Sankyo: Global mid-size Japanese pharmaceutical company with deep cardiology heritage and a growing specialty/oncology pipeline. Comparable to Servier in cardiovascular legacy, oncology pivot, and export-oriented manufacturing footprint.
• Chiesi Farmaceutici: Family-owned, mid-size European pharmaceutical group with focus on cardiovascular, respiratory, and specialty therapeutics, plus recent move into biotech. Comparable to Servier in private governance, therapeutic mix, and European manufacturing scale.
• Boehringer Ingelheim: Privately held, family/foundation-governed global pharmaceutical company with a strong cardiometabolic, respiratory, and specialty portfolio. Closest structural peer to Servier given shared private governance, mid-size scale, and leadership in cardiovascular and metabolic disease.

Emerging players

• STADA Arzneimittel: European-focused generics and specialty pharmaceutical group with strong cardiovascular and consumer health portfolios. Comparable to Servier's generic and established branded medicine business, particularly for products supplied from the Arklow facility.

Broad incumbents

• Sanofi: Global pharmaceutical major with established cardiovascular, diabetes, and specialty care franchises. Comparable to Servier in therapeutic overlap (hypertension, diabetes, oncology) but operates at substantially larger scale across broader indications.
• Bayer Pharmaceuticals: Large diversified pharmaceutical division of Bayer AG with leading cardiovascular (Xarelto) and women's health franchises. Comparable to Servier's cardiometabolic core but at significantly larger scale and within a broader crop science/consumer health conglomerate.
• Takeda Pharmaceutical: Global pharmaceutical major with strong oncology, neuroscience, and rare disease presence plus manufacturing in Europe. Comparable to Servier in therapeutic breadth and European manufacturing footprint, but at materially larger scale post-Shire integration.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/servier
• Facebookfacebook.com/Servier
• LinkedInlinkedin.com/company/servier-ireland
• Instagraminstagram.com/servier_group

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier Ireland